Cost-Effectiveness of Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: A Systematic Review.
Sam P J van Dijk, Matthew M K Blanco, Ali Akhavan et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the cost-effectiveness of radiofrequency ablation (RFA) compared to surgery for benign non-functioning thyroid nodules. Thirteen studies were included, revealing that RFA had incremental cost-effectiveness ratios (ICERs) ranging from -$14,994 to $98,858 per QALY gained. Overall, RFA was generally associated with lower costs and greater effectiveness.
Key findings
- ICERs for RFA versus surgery ranged from -$14,994 to $98,858 per QALY gained.
- RFA had a median total cost of $2499 compared to $3579 for surgery.
- Post hoc estimates of net monetary benefit favored RFA at $50,000 and $100,000 willingness-to-pay thresholds.
- Overall certainty of economic evidence was rated as low.
Why it matters
Understanding the cost-effectiveness of RFA versus surgery for benign thyroid nodules can inform clinical decision-making and resource allocation, particularly in settings where healthcare costs are a significant concern.
What to keep in mind
Methodological heterogeneity among studies limited comparability, and the overall certainty of economic evidence was rated as low.